Innoviva (INVA) Cash from Financing Activities (2010 - 2026)
Innoviva's (INVA) quarterly Cash from Financing Activities came in at -$20.1 million in Q1 2026, down 11108.74% YoY from N/an in Q1 2025, and down 264.16% on a QoQ basis from $12.3 million in Q3 2025.
Innoviva (INVA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Cash from Financing Activities data on file, last reported at -$20.1 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 11108.74% year-over-year to -$20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.4 million (up 77.05% YoY) and the FY2025 annual result came in at $8.6 million, up 163.56% from the prior year.
- Cash from Financing Activities eased to -$20.1 million in Q1 2026, from $12.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $60.3 million in Q1 2022 to a low of -$157.2 million in Q3 2023.
- A 5-year average of -$25.6 million and a median of -$9.2 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 383.11% — and 2026, when it plunged 11108.74%.
- Tracing INVA's Cash from Financing Activities over 5 years: stood at -$45.6 million in 2022, then tumbled by 245.1% to -$157.2 million in 2023, then surged by 91.08% to -$14.0 million in 2024, then jumped by 187.49% to $12.3 million in 2025, then slumped by 264.16% to -$20.1 million in 2026.
- The last three Cash from Financing Activities figures came in at -$20.1 million (Q1 2026), $12.3 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -29.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.41 Mn |
| Jun 30, 2026 | -29.41 Mn |
| Mar 31, 2026 | -20.15 Mn |
| Mar 31, 2026 | -20.15 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Sep 30, 2024 | -14.03 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Mar 31, 2024 | -9.17 Mn |
| Mar 31, 2024 | -9.17 Mn |
| Sep 30, 2023 | -157.25 Mn |
| Sep 30, 2023 | -157.25 Mn |
| Jun 30, 2023 | -9.21 Mn |
| Jun 30, 2023 | -9.21 Mn |